Researcher Database | Faculty of Pharmaceutical Sciences Department of Pharmacy | Maiko Machida |

（Last updated : 2025-09-19 17:50:49）

Visruth.jpg not found

Maiko Machida

Department / Course Hokkaido University of Science Faculty of Pharmaceutical Sciences Department of Pharmacy

Job Professor

Academic background
2007/08 Degree Acquisition
1998/03 Degree Acquisition

Present specialized field
Others, Others

Book and thesis
Papers	Matsuda index adjusted for sustained hyperglycemia via propensity scores outperforms homeostatic model assessment for insulin resistance in identifying insulin—requiring gestational diabetes mellitus SAGE Open Medicine 13,pp.1-11 (Co-authored) 2025/09
Papers	Clinical research on withdrawal symptoms of dexmedetomidine in neonates.,pp.33-37 (Co-authored) 2024/04/30
Papers	Integrated predictors by propensity scoring with tumor markers and plasma levels of microRNA-21-5p, IL-17, and IL-10 complement early detection of hepatocellular carcinoma in patients with liver cirrhosis. Technology in Cancer Research & Treatment 20,pp.1-15 (Co-authored) 2023/11/13
Papers	A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer Journal of Pharmaceutical Health Care and Sciences 8 (29) (Co-authored) 2022/10/11
Papers	The Concentration of 8-Hydroxy-2′-Deoxyguanosine in Plasma During the Menstrual Cycle in Young Japanese Women Women's health reports 3 (1),pp.267-273 (Co-authored) 2022/03/01
Display All（17）

Academic conference presentation
2025/03/27	Effects of tetracycline antibiotics in an inflammation model using RAW264.7 cells
2025/03/27	The involvement of miRNAs in the changes of platelet/lymphocyte ratio due to pembrolizumab treatment differs between non-small cell lung cancer tumors.
2025/03/27	The involvement of miRNAs in the changes of the Systemic immune-inflammation index due to pembrolizumab treatment differs between non-small cell lung cancer tumors.
2025/03/27	Regulatory factors of the neutrophil/lymphocyte ratio during pembrolizumab treatment differ between non-small cell lung cancer types.
2025/03/27	Search for gastrointestinal drugs effective in preventing the onset of everolimus-induced interstitial lung disease using a drug adverse reaction database and in vitro methods
Display All（28）